Investing.com - Zevra Therapeutics (NASDAQ: ZVRA) reported second quarter EPS of $-0.480, $0.02 worse than the analyst estimate of $-0.460. Revenue for the quarter came in at $445M versus the consensus estimate of $4.41M.
Zevra Therapeutics's stock price closed at $6.78. It is up 43.340% in the last 3 months and up 25.560% in the last 12 months.
Zevra Therapeutics saw 3 positive EPS revisions and 2 negative EPS revisions in the last 90 days. See Zevra Therapeutics's stock price’s past reactions to earnings here.
According to InvestingPro, Zevra Therapeutics's Financial Health score is "fair performance".
Check out Zevra Therapeutics's recent earnings performance, and Zevra Therapeutics's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar